Drugs / Regular Human Insulin
Regular Human Insulin
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials · 1 met primary | ||||||
| Phase 1 | NCT02269735 | Nov 2014 → Jul 2016 | type 1 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT00862849 | Mar → Jun 2009 | diabetes mellitus | Halozyme Therapeutics | Completed | Met primary |
| Phase 23 trials · 1 met primary | ||||||
| Phase 2 | NCT02415556 | Oct 2015 → May 2020 | type 2 diabetes mellitus | Beth Israel Deaconess Medical Center | Completed | Mixed |
| Phase 2 | NCT00883558 | May 2009 → Feb 2010 | type 1 diabetes mellitus | Halozyme Therapeutics | Completed | Met primary |
| Phase 2 | NCT01000922 | Jun 2006 → Jan 2008 | diabetes mellitus | Biodel | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00447213 | Apr 2007 → May 2008 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT01648218 | Aug 2012 → Apr 2013 | — | Vancouver General Hospital | Terminated | No outcome recorded Stop: Enrollment |
| Phase not applicable1 trial | ||||||
| — | NCT01601561 | Jun 2010 → Dec 2012 | — | McGill University Health Centre/Research Institute of the McGill University Health Centre | Unknown | No outcome recorded |
| Comparator or background therapy11 trials | ||||||
| Phase 1 | NCT01490762 Comparator | Dec 2011 → May 2012 | — | Mannkind Corporation | Completed | No outcome recorded |
| Phase 1 | NCT00511979 Comparator | Aug 1999 → Feb 2000 | — | Mannkind Corporation | Completed | No outcome recorded |
| Phase 1/2 | NCT02739906 Comparator | Apr → Aug 2016 | type 1 diabetes mellitus | Adocia | Completed | Met primary |
| Phase 3 | NCT00849576 Comparator | Apr → Aug 2008 | type 2 diabetes mellitus | Biodel | Completed | No outcome recorded |
| Phase 3 | NCT00668850 Comparator | Apr 2008 → Aug 2011 | diabetes mellitus | Generex Biotechnology Corp. | Unknown | No outcome recorded |
| Phase 3 | NCT00542633 Comparator | Dec 2006 → Aug 2008 | type 2 diabetes mellitus | Biodel | Completed | No outcome recorded |
| Phase 3 | NCT00542724 Comparator | Sep 2006 → Jul 2008 | type 1 diabetes mellitus | Biodel | Completed | No outcome recorded |
| Phase 3 | NCT00127634 Comparator | Jul 2005 → May 2008 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT02556918 Background | Jan 2016 → Nov 2018 | hyperglycemia | Emory University | Completed | No outcome recorded |
| Phase 4 | NCT02443402 Background | Jan → Dec 2016 | coronary artery disorder | Emory University | Completed | No outcome recorded |
| Phase 4 | NCT01417897 Comparator | Sep 2011 → May 2012 | type 2 diabetes mellitus | ikfe-CRO GmbH | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 19 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Regular Human Insulin | “The purpose of the study is to compare the human insulin inhalation powder plus insulin glargine with injected insulin (regular human insulin or insulin lispro) plus insulin...” NCT00447213 ↗18“receive AIR insulin or SC insulin (regular human insulin or insulin lispro) at mealtimes.” PMID 19772449 ↗ Sep 2009 |
| Known as | Huminsulin Normal | “Regular human insulin (Huminsulin® Normal) individualised single subcutaneous injection followed by test meal intake” NCT02739906 ↗ |
| Known as | RHI | “Regular Human Insulin (RHI)” NCT02269735 ↗ |
| Modality | Protein / enzyme biologic | “Biological: Regular Human Insulin (RHI)” NCT02269735 ↗ |
| Route | Subcutaneous | “receive AIR insulin or SC insulin (regular human insulin or insulin lispro) at mealtimes.” PMID 19772449 ↗ Sep 2009 |